1. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-69. [DOI:10.1146/annurev.neuro.30.051606.094313]

2. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-55. [DOI:10.1056/NEJMra052130]

3. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014;10:225. [DOI:10.1038/nrneurol.2014.37]

4. Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15:146-56. [DOI:10.7224/1537-2073.2012-053]

5. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002;159:1862-8. [DOI:10.1176/appi.ajp.159.11.1862]

6. Dargahi N, Katsara M, Tselios T, Androutsou ME, De Courten M, Matsoukas J, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017;7:78. [DOI:10.3390/brainsci7070078]

7. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun 2005;6:375. [DOI:10.1038/sj.gene.6364237]

8. Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011;77:355-63. [DOI:10.1212/WNL.0b013e3182270402]

9. S Weber M, Menge T, Lehmann-Horn K, C Kronsbein H, Zettl U, Sellner J, et al. Current treatment strategies for multiple sclerosis-efficacy versus neurological adverse effects. Curr Pharm Des 2012;18:209-19. [DOI:10.2174/138161212799040501]

10. Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis. CNS Drugs 2008;22:827-39. [DOI:10.2165/00023210-200822100-00004]

11. Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 2016;86:1014-21. [DOI:10.1212/WNL.0000000000002469]

12. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol 2013;70:356-63. [DOI:10.1159/000355140]

13. Giesser BS. Gender issues in multiple sclerosis. Neurologist 2002;8:351-6. [DOI:10.1097/00127893-200211000-00003]

14. MacLurg K, Reilly P, Hawkins S, Gray O, Evason E, Whittington D. A primary care-based needs assessment of people with multiple sclerosis. Br J Gen Pract 2005;55:378-83.

15. Jongen PJ, Ter AH, Brands AM. Cognitive impairment in multiple sclerosis. Minerva Medica 2012;103:73-96.

16. Lincoln NB, Dent A, Harding J, Weyman N, Nicholl C, Blumhardt LD, et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;72:93-8. [DOI:10.1136/jnnp.72.1.93]

17. Sartori E, Edan G. Assessment of cognitive dysfunction in multiple sclerosis. J Neurol Sci 2006;245:169-75. [DOI:10.1016/j.jns.2005.07.016]

18. Amato MP, Portaccio E, Stromillo ML, Goretti B, Zipoli V, Siracusa G, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008;71:632-8. [DOI:10.1212/01.wnl.0000324621.58447.00]

19. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment: A clinical test. Arch Neurol 1978;35:364-7. [DOI:10.1001/archneur.1978.00500300038006]

20. Spencer RJ, Wendell CR, Giggey PP, Seliger SL, Katzel LI, Waldstein SR. Judgment of Line Orientation: an examination of eight short forms. J Clin. Exp Neuropsychol 2013;35:160-6. [DOI:10.1080/13803395.2012.760535]

21. Cheadle C, Vawter MP, Freed WJ, Becker KG. Analysis of microarray data using Z score transformation. J Mol Diagn 2003;5:73-81. [DOI:10.1016/S1525-1578(10)60455-2]

22. Benesty J, Chen J, Huang Y, Cohen I. Pearson correlation coefficient. In: Cohen I, Huang Y, Chen J, Benesty J, Editors. Noise reduction in speech processing. Berlin, Heidelberg: Springer; 2009. P.1-4. [DOI:10.1007/978-3-642-00296-0_5]

23. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003;16:283-8. [DOI:10.1097/01.wco.0000073928.19076.84]

24. Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry 2009;80:767-72. [DOI:10.1136/jnnp.2008.165449]

25. Smerbeck AM, Parrish J, Serafin D, Yeh EA, Weinstock-Guttman B, Hoogs M, et al. Visual-cognitive processing deficits in pediatric multiple sclerosis. Mult Scler J 2011;17:449-56. [DOI:10.1177/1352458510391689]

26. Yalachkov Y, Bergmann J, Soydaş D, Buschenlange C, Fadai Motlagh LY, Naumer MJ, et al. Cognitive impairment in multiple sclerosis is reflected by increased susceptibility to the sound-induced flash illusion. Front Neurol 2019;10:373. [DOI:10.3389/fneur.2019.00373]

27. Rahn K, Slusher B, Kaplin A. Cognitive impairment in multiple sclerosis: a forgotten disability remembered. Cerebrum 2012;2012:14.

28. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-51. [DOI:10.1016/S1474-4422(08)70259-X]

29. Lazeron RH, Boringa JB, Schouten M, Uitdehaag BM, Bergers E, Lindeboom J, et al. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler J 2005;11:524-31. [DOI:10.1191/1352458505ms1201oa]

30. Svendsen B, Grytten N, Bø L, Aarseth H, Smedal T, Myhr KM. The economic impact of multiple sclerosis to the patients and their families in Norway. Eur J Health Econ 2018;19:1243-57. [DOI:10.1007/s10198-018-0971-5]